Navigation Links
Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
Date:1/9/2009

Stock of Avigen.

As the general partner of BVF and BVF2, the manager of BVLLC and the investment adviser of ILL10, Partners may be deemed to beneficially own the 8,819,600 shares of Common Stock of Avigen beneficially owned in the aggregate by BVF, BVF2, BVLLC and ILL10. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the 8,819,600 shares of Common Stock of Avigen beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc. may be deemed to beneficially own the 8,819,600 shares of Common Stock of Avigen beneficially owned by BFV Inc.

None of Messrs. Nodelman, Perry or Coppedge directly owns any shares of Common Stock of Avigen. As a members of a "group" for the purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended, each of Messrs. Nodelman, Perry and Coppedge may be deemed to beneficially own the 8,819,600 shares of Common Stock of Avigen beneficially owned in the aggregate by the other participants named herein. Each of Messrs. Nodelman, Perry and Coppedge disclaims beneficial ownership of such shares of Common Stock.


'/>"/>
SOURCE Biotechnology Value Fund, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
2. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
3. Micromet Added to NASDAQ Biotechnology Index
4. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
5. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
6. Yongye Biotechnology Announces Record Third Quarter Results
7. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
10. InNexus Biotechnology Receives Patent Grants in Europe
11. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...EN,Italy,November24/PRNewswire/--HealthRoboticstod...ewithagroupofselected,investors.Thisrecentlyformed...RoboticsCanada,Inc.andwillmarket,install,andsuppor...ncludesthe,revolutionaryproductofferingsi.v.STATIO...aInc.willalsoprovideassistanceonan"asneeded,basis"...
(Date:11/24/2009)...TTLE,Nov.24/PRNewswire-FirstCall/--CellTherapeutic...tatthe21stAnnualPiperJaffrayHealthCareConference.T...kPalaceHotel. ,, CTIwillpresentonTuesday,Decemb...audiowebcastofCTI,spresentationwillbeavailableat w...orreplayafterwards. , ,PiperJaffrayHealthCareConf...
(Date:11/23/2009)...omputing promises ultra-fast communication, comput...information. But trying to use quantum states as c...siness. Now two physicists have shown, mathematica...ntum communication, while keeping the information ...e of Physical Review Letters and highlighted wit...
(Date:11/23/2009)...SISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioScie...ctdevelopmentcompanythatidentifiesandadvancesadive...iousstagesofdevelopment,todayreportedthatCytopia(A...uatingCYT387,apotent,orally-administeredJAK1/JAK2i...hester,Minnesota.AproposaltomergeCytopiaintoYMhasb...
Breaking Biology Technology:Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...e profiling of protein biomarkers in tissue now, ...utions through Brigham and Women,... 29 HistoRx, Inc., announced today,that the patho... (BWH) will,begin making the company,s AQUA(R) tec...to the more than 900 Dana-Farber/Harvard Cancer Ce...
...atic, or fully differentiated, human cells back to...any of the significant scientific and social chall...help realize the promise of regenerative medicine....monstrated that such a transformation (reprogrammi...nefficient and, when it does work, poorly understo...
..., Inc. (Nasdaq:,SQNM) today announced that a live ...will be provided for its analyst and investor brie...enatal Diagnostics." Details of the,event are as f...nvasive Prenatal Diagnostics, When: Tuesday, ... http://www.sequenom.com , Agenda: Hosted by:...
Other Biology Technology:HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center 2HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center 3New insights into cellular reprogramming revealed by genomic analysis 2Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3 2
(Date:11/25/2009)...e heart pumps some 250 million liters of blood thr... fibers of the heart have to be extremely durable....er, vice chair of the Department of Medicine III a...Dr. H. A. Katus), has discovered a protein that is...cular unit, the sarcomere. In cooperation with oth...
(Date:11/25/2009)... just as vital to your health as what you eat, fou...l Studies. Their experiments in mice revealed that... in the liverthe body,s metabolic clearinghouseis ...dy,s circadian clock as conventional wisdom had it... a large number of genes completely independent of...
(Date:11/24/2009)...) today named 12 new grant recipients for 2009. Th...ive work across a broad spectrum of lupus research... and potential to drive scientific discovery to ul...ase of systemic lupus. , The 2009 grants go to b...he nation and include interdisciplinary and highly...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Tyco International to Present at the Citi Industrial Manufacturing 26amp 3B Transportation Conference 60962 1Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 1Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 3Pharma and Biotech Leaders to Converge in Shanghai 14765 1Pharma and Biotech Leaders to Converge in Shanghai 14765 2
...ow highlight research in the ESA journals Frontie...ological Applications and Ecological Monographs ... wildfire severity but may invite invasives , ...compares the effectiveness of fire fuel reduction ...ogate Study. Four articles examine the effects of ...
.... Prenatal exposure to an insecticide commonly us...ty epidemic in women, according to a new study inv...rs. , More than 250 mothers who live along and ea...xposure to DDE a breakdown of DDT. The study, pub...on of Occupational and Environmental Medicine , a...
...as a moon named Deimos, so it seems only appropria... have its own DEIMOS. This DEIMOS, however, is an ...vements of fish and zooplankton. , MARS, which st...sists of a node the size of two compact cars that ...rnet connection for scientific instruments. Connec...
Other Biology News:Highlights from the March editions of ESA journals 2Highlights from the March editions of ESA journals 3Exposure to insecticide may play role in obesity epidemic among some women 2DEIMOS joins MARS and its satellite of instruments on seafloor 2DEIMOS joins MARS and its satellite of instruments on seafloor 3
QuantiChrom Zinc Assay Kit from BioAssay Systems
Mouse Anti-Human PDGF R beta Monoclonal Antibody, Unconjugated, Clone PR7212 from R&D Systems
Mouse IL-23, Unconjugated from R&D Systems
Rabbit Serum from Lifeblood Medical, Inc.
Biology Products: